REZLIDHIA (olutasidenib)
TherapyRigel Pharmaceuticals
REZLIDHIA (olutasidenib) from Rigel Pharmaceuticals is a targeted therapy used in IDH1-mutant relapsed or refractory AML.
Approvals
1
Indications
1
Biomarkers
1
Mapped tests
1
Where this therapy is approved with a companion diagnostic
Each row represents a defined combination of indication, biomarker criteria, and REZLIDHIA. Select a testing pathway to see the eligible companion diagnostic tests.
Indication-specific approvals
Approvals where REZLIDHIA is tied to a specific indication and biomarker definition.
| Indication | Biomarker criteria | Notes | |
|---|---|---|---|
Acute Myeloid Leukemia (AML) Heme · Leukemia | IDH1
| View testing pathway → |
Tumor-agnostic approvals
Approvals defined at the solid tumor level where biomarker criteria determine eligibility for REZLIDHIA.
No tumor-agnostic companion diagnostic approvals are currently mapped for this therapy.
Tests used in these approvals
These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering REZLIDHIA for eligible patients.
Test
Abbott RealTime IDH1
Abbott Molecular, Inc.
Method
PCR
Specimen
Whole blood
1 approvalView test profile →